Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group, Clin. Infect. Dis, vol.46, pp.1813-1821, 2008. ,
Matrix-assisted laser desorption ionization time-of-flight mass spectrometry for fast and accurate identification of clinically relevant Aspergillus species, Clin. Microbiol. Infect, vol.17, pp.750-755, 2011. ,
URL : https://hal.archives-ouvertes.fr/pasteur-01405253
Azoleresistance in Aspergillus: proposed nomenclature and breakpoints, Drug Resist Updat, vol.12, pp.141-147, 2009. ,
Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes, Clin. Infect. Dis, vol.46, pp.201-211, 2008. ,
, Briefing document for voriconazole (oral and intravenous formulations), 2001.
Antifungal drugs in pregnancy: a review, Expert Opin. Drug Saf, vol.2, pp.475-483, 2003. ,
Safety of fluconazole in the treatment of vaginal candidiasis. A prescription-event monitoring study, with special reference to the outcome of pregnancy, Eur. J. Clin. Pharmacol, vol.46, pp.115-118, 1994. ,
Prenatal exposure to fluconazole: an identifiable dysmorphic phenotype, Birth Defects Res. A Clin. Mol. Teratol, vol.73, pp.919-923, 2005. ,
Fluconazole-induced congenital anomalies in three infants, Clin. Infect. Dis, vol.22, pp.336-340, 1996. ,
, Drugs in pregnancy and lactation, vol.1, 2008.